Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis. Issue 1 (December 2015)

Record Type:
Journal Article
Title:
Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis. Issue 1 (December 2015)
Main Title:
Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis
Authors:
Gillmore, Julian
Falk, Rodney
Maurer, Mathew
Hanna, Mazen
Karsten, Verena
Vest, John
Gollob, Jared
Hawkins, Philip
Abstract:
Is Part Of:
Orphanet journal of rare diseases. Volume 9:Issue 1(2014)
Journal:
Orphanet journal of rare diseases
Issue:
Volume 9:Issue 1(2014)
Issue Display:
Volume 9, Issue 1 (2014)
Year:
2014
Volume:
9
Issue:
1
Issue Sort Value:
2014-0009-0001-0000
Page Start:
1
Page End:
2
Publication Date:
2015-12
Subjects:
Rare diseases -- Periodicals
Genetic disorders -- Periodicals
Orphan drugs -- Periodicals
616
Journal URLs:
http://pubmedcentral.com/tocrender.fcgi?journal=401&action=archive ↗
http://www.ojrd.com/home/ ↗
http://link.springer.com/ ↗
DOI:
10.1186/1750-1172-10-S1-O21 ↗
Languages:
English
ISSNs:
1750-1172
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
9895.xml